Hologic (HOLX) stock has been experiencing a declining trend as it navigates an evolving geopolitical and macroeconomic landscape. The shares of the Marlborough, MA-based women’s health company have declined 24.7% over the past six months, significantly below the industry’s 10.7% drop and the S&P 500 composite’s modest 0.3% fall.Among its industry peers, QIAGEN (QGEN) has comparatively fared better, while Abbott (ABT) has shown even more resilience in the same time frame.Six-Month Price ComparisonImage Sour ...